EML4-ALK variant 1 (E13;A20) is a stable fusion isoform with longer PFS on 2nd-gen ALK-TK...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-ALK-EML4-V1-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-ALK-FUSION |
|---|---|
| Variant | EML4-ALK variant 1 (E13;A20) |
| Disease | DIS-NSCLC |
| ESCAT tier | IA |
| Recommended combinations | alectinib monotherapy, lorlatinib monotherapy |
| Evidence summary | EML4-ALK variant 1 (E13;A20) is a stable fusion isoform with longer PFS on 2nd-gen ALK-TKIs vs variant 3. Standard 1L is alectinib or lorlatinib; v1 patients show particularly durable responses to alectinib (~3-year median PFS in subset analyses of ALEX and J-ALEX). |
Notes
ESCAT IA. Variant typing not strictly required for 1L decision but informs prognosis and surveillance intensity. RNA-NGS reports variant.
Used By
Actionability
BMA-RET-KIF5B-NSCLC- KIF5B-RET is the most common RET fusion in NSCLC (~70% of RET+ NSCLC). Treatment is ident...